Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904335 | 0.91 | SCN9A (0.48) | SCN9ACYP1A2CYP2C8CYP2C9HTR2A | |
| SCHEMBL13006934 | 0.90 | SCN9A (0.49) | SCN9ACYP1A2CYP2C9HTR2ACYP3A4 | |
| SCHEMBL12051142 | 0.89 | SCN9A (0.52) | SCN9ACYP1A2CYP2C8CYP2C9HTR2A | |
| SCHEMBL15294529 | 0.84 | SCN9A (0.45) | SCN9ACYP1A2CYP2C8CYP2C9HTR2A | |
| SCHEMBL6367989 | 0.84 | SCN9A (0.40) | SCN9ACYP1A2CYP2C8CYP2C9HTR2A | |
| SCHEMBL6368385 | 0.81 | SCN9A (0.42) | SCN9ACYP3A4CYP2C19 | |
| SCHEMBL903153 | 0.80 | SCN9A (0.48) | SCN9ACYP1A2CYP2C9HTR2ACYP3A4 | |
| SCHEMBL5517804 | 0.80 | HTR2A (0.52) | SCN9ACYP1A2CYP2C9HTR2ACYP3A4 | |
| SCHEMBL14147690 | 0.80 | CYP3A4 (0.59) | SCN9ACYP1A2CYP2C9HTR2ACYP3A4 | |
| SCHEMBL12051151 | 0.78 | HTR2A (0.52) | SCN9ACYP1A2CYP2C9HTR2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20120122887-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122887-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | SCN9A 829/4885CYP1A2 2833/4885CYP2C8 1783/4885 |
| US-20130288957-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS | IL36G, IL17A, IL6ST | SCN9A 400/4885CYP1A2 182/4885CYP2C8 17/4885 |
| US-20130261050-A1 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION | SLC10A1, HAVCR2, GOT2 | SCN9A 3205/4885CYP1A2 414/4885CYP2C8 400/4885 |
| US-20130261134-A1 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR | SLC10A1, HAVCR2, ABL1 | SCN9A 651/4885CYP1A2 2228/4885CYP2C8 1086/4885 |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | HAVCR2, EIF2AK2, SLC10A1 | SCN9A 3837/4885CYP1A2 2933/4885CYP2C8 2071/4885 |
| US-20140057928-A1 | SOLID STATE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | SCN9A 829/4885CYP1A2 2833/4885CYP2C8 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.